CBRNE - Viral Hemorrhagic Fevers
- Author: David C Pigott, MD, RDMS, FACEP; Chief Editor: Robert G Darling, MD, FACEP more...
Background
Viral hemorrhagic fevers (VHFs) are a group of febrile illnesses caused by RNA viruses from several viral families. These highly infectious viruses lead to a potentially lethal disease syndrome characterized by fever, malaise, vomiting, mucosal and gastrointestinal (GI) bleeding, edema, and hypotension. The 4 viral families known to cause VHF disease in humans include the Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae. General characteristics of these viral families can be found in the table below.
Table. Viral Families Causing Viral Hemorrhagic Fever (Open Table in a new window)
| Virus Family | Disease (Virus) | Natural Distribution | Usual Source of Human Infection | Incubation (Days) |
| Arenaviridae | ||||
| Arenavirus | Lassa fever | Africa | Rodent | 5-16 |
| Argentine HF (Junin) | South America | Rodent | 7-14 | |
| Bolivian HF (Machupo) | South America | Rodent | 9-15 | |
| Brazilian HF (Sabia) | South America | Rodent | 7-14 | |
| Venezuelan HF (Guanarito) | South America | Rodent | 7-14 | |
| Bunyaviridae | ||||
| Phlebovirus | Rift Valley fever | Africa | Mosquito | 2-5 |
| Nairovirus | Crimean-Congo HF | Europe, Asia, Africa | Tick | 3-12 |
| Hantavirus | Hemorrhagic fever with renal syndrome, hantavirus pulmonary syndrome | Asia, Europe, worldwide | Rodent | 9-35 |
| Filoviridae | ||||
| Filovirus | Marburg and Ebola | Africa | Unknown | 3-16 |
| Flaviviridae | ||||
| Flavivirus | Yellow fever | Tropical Africa, South America | Mosquito | 3-6 |
| Dengue HF | Asia, Americas, Africa | Mosquito | Unknown for dengue HF, 3-5 for dengue |
Arenaviridae
Arenaviridae are spread to humans by rodent contact and include Lassa virus in Africa and several rare South American hemorrhagic fevers such as Machupo, Junin, Guanarito, and Sabia. Lassa virus is the most clinically significant of the Arenaviridae, accounting for serious morbidity and mortality in West Africa.
Lassa fever first appeared in Lassa, Nigeria, in 1969. It has been found in all countries of West Africa and is a significant public health problem in endemic areas. In populations studied, Lassa fever accounts for 5-14% of hospitalized febrile illnesses. Its natural reservoir is a small rodent whose virus-containing excreta is the source of transmission.
Mastomys rodent, natural host of Lassa virus. Image courtesy of the Centers for Disease Control and Prevention. Bunyaviridae
This group includes Rift Valley fever (RVF) virus, Crimean-Congo hemorrhagic fever (CCHF) virus, and several hantaviruses. The RVF and CCHF viruses are both arthropod-borne viruses. RVF virus, an important African pathogen, is transmitted to humans and livestock by mosquitos and by the slaughter of infected livestock. CCHF virus is carried by ticks and causes a fulminant, highly pathogenic form of VHF notable for aerosol transmission of infective particles. Outbreaks of CCHF have occurred in Africa, Asia, and Europe.
Bunyavirus infection. Ecchymoses encompassing left upper extremity one week after onset of CCHF. Ecchymoses often are accompanied by hemorrhage in other locations: epistaxis, puncture sites, hematemesis, melena, and hematuria. Image provided by Robert Swaneopoel, PhD, DTVM, MRCVS, National Institute of Virology, Sandringham, South Africa. Many hantaviruses are spread worldwide, causing 2 major syndromes: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). They are divided into Old World hantaviruses (such as the prototypical Hantaan virus of Korea), which generally cause HFRS, and New World hantaviruses, causing HPS. Rodents carry both types. A previously undiscovered Hantavirus, Sin Nombre virus, was the cause of an outbreak of highly lethal HPS in the southwestern US in 1993. More than 450 cases have been identified in the US since 1993 with a 35% mortality rate.[1]
Filoviridae
The most notorious of the VHF viruses, including Ebola and Marburg viruses, belong to the Filoviridae family. Ebola virus first was described in 1976 after outbreaks of a febrile, rapidly fatal hemorrhagic illness were reported along the Ebola River in Zaire (now the Democratic Republic of the Congo) and Sudan. Sporadic outbreaks have continued since that time, usually in isolated areas of central Africa. An outbreak in Kikwit, Zaire, in 1995 led to 317 confirmed cases, with an 81% mortality rate. Two thirds of the patients were among health care workers caring for infected individuals. An outbreak in Uganda in late 2000 resulted in 425 cases and claimed 225 lives.
In September 2007, the cause of a VHF outbreak in the Congo was identified as Ebola. Ebola has 4 distinct subtypes: Ebola-Zaire, Ebola-Sudan, Ebola-Ivory Coast, and Ebola-Reston, a form that causes illness in nonhuman primates, and as has been recently discovered, in pigs.[2] A 2007 Ebola outbreak in Uganda, however, has been attributed to a new form of Ebola. This new Ebola subtype, which appears to be closely related to Ebola-Ivory Coast, has been given the proposed name Bundibugyo Ebola virus (named after the Bundibugyo district in Western Uganda).[3]
The natural reservoir of Ebola virus remains unknown, although some recent studies have suggested that bats may be a potential reservoir for Ebola.[4]
Ebola virus. Electron micrograph courtesy of the Centers for Disease Control and Prevention. Marburg virus, named after the German town where it first was reported in 1967, is another highly pathogenic member of the Filoviridae family that is traced to central Africa. As in Ebola, the natural host for the virus is unknown. Marburg virus was contracted by a traveler to central Africa in 1987 and has been endemic since 1998 in Durba, Democratic Republic of the Congo, and in persons exposed in gold mines. Marburg virus was determined to be the causative agent in a 2004-2005 outbreak of hemorrhagic fever in Angola that led to 252 confirmed cases and 227 deaths (90% case-fatality rate).
Marburg virus. Negative stain image courtesy of the Centers for Disease Control and Prevention. Flaviviridae
Yellow fever and dengue fever are the most well known diseases caused by flaviviruses. Both are mosquito-borne; yellow fever is found in tropical Africa and South America, and dengue fever is found in Asia, Africa, and the Americas. They are notable for their significant effect on prior military campaigns and their continued presence throughout endemic areas.
Due to a resurgence in the last 3 decades, dengue fever is now considered second only to malaria in terms of importance as a tropical disease. Multiple recent large outbreaks have occurred throughout the tropics, with the most severe outbreaks occurring in Southeast Asia and the western Pacific regions. Transmission is via the bite of the infected female Aedes mosquito, although dengue can also be transmitted via transfusion.[5]
Pathophysiology
The primary defect in patients with viral hemorrhagic fever (VHF) is that of increased vascular permeability. Hemorrhagic fever viruses have an affinity for the vascular system, leading initially to signs such as flushing, conjunctival injection, and petechial hemorrhages, usually associated with fever and myalgias. Later, frank mucous membrane hemorrhage may occur, with accompanying hypotension, shock, and circulatory collapse. The relative severity of the clinical presentation may vary depending on the virus in question, amount, and route of exposure.
In acute disease, patients are extremely viremic, and messenger ribonucleic acid (mRNA) evidence of multiple cytokine activation exists. In vitro studies reveal these cytokines lead to shock and increased vascular permeability, the basic pathophysiologic processes most often seen in viral hemorrhagic fever infection. Another prominent pathologic feature is pronounced macrophage involvement. Inadequate or delayed immune response to these novel viral antigens may lead to rapid development of overwhelming viremia. Extensive infection and necrosis of affected organs also are described. Hemorrhagic complications are multifactorial and are related to hepatic damage, consumptive coagulopathy, and primary marrow injury to megakaryocytes. Aerosol transmission of some viral hemorrhagic fever infections is reported among nonhuman primates and likely is a mode of transmission in patients with severe infection.
Multisystem organ failure affecting the hematopoietic, neurologic, and pulmonary systems often accompanies the vascular involvement. Hepatic involvement varies with the infecting organism and is at times seen with Ebola, Marburg, RVF, CCHF, and yellow fever. Renal failure with oliguria is a prominent feature of HFRS seen in Hantavirus infection and may be seen in other VHFs as intravascular volume depletion becomes more pronounced. Bleeding complications are particularly prominent with Ebola, Marburg, CCHF, and the South American arenaviruses.
Although the pathophysiology of dengue infection is complex and incompletely understood, severe dengue infection can be differentiated from milder forms by the presence of increased vascular permeability. The greatest risk factor for severe dengue infection is secondary infection with a dengue serotype different from the initial dengue infection. This increased vascular permeability is thought to be secondary to widespread T-cell activation and apoptosis and is also thought to be related to a process known as antibody-dependent enhancement, best described as the balance between neutralizing versus enhancing antibodies after an initial dengue infection, which can contribute to the severity of secondary dengue infection.
Epidemiology
Frequency
United States
Cases of viral hemorrhagic fever in the United States are extremely rare and usually are found in patients who recently have visited endemic areas or among those with potential occupational exposure to hemorrhagic fever viruses. Lassa fever has been reported in the United States in travelers from West Africa and was most recently reported in the United States in August 2004. In 1994, a virologist working with Sabia, a Brazilian HF virus, accidentally contracted the disease. Sporadic cases of HPS due to Sin Nombre virus continue to be reported throughout the southwestern United States.[6]
No human cases of Ebola or Marburg virus disease have been reported in the United States. In 1989, an outbreak of hemorrhagic fever among imported macaque monkeys in Reston, Virginia, led to the discovery of Ebola-Reston, a variant of Ebola virus that originated in the Philippines and does not cause disease in humans.
An estimated 100-200 cases of imported dengue fever are reported in the United States each year. Occasional dengue outbreaks have occurred in the United States, and well-documented local transmission of dengue continues to occur in south Florida, specifically in Key West.[7]
International
Lassa fever is responsible for an estimated 100,000-300,000 infections per year, with 5,000 deaths. Cases have been reported throughout West Africa, particularly in Nigeria, Sierra Leone, Guinea, and Liberia. Other arenaviruses are responsible for sporadic VHF outbreaks throughout South America.
Rift Valley fever (RVF) virus and Crimean-Congo hemorrhagic fever (CCHF) are responsible for intermittent epidemics in Africa (for RVF) and in areas of Africa, Asia, and Europe (for CCHF). HFRS due to Hantavirus infection continues to be an ongoing health concern, particularly in Asia, affecting up to 200,000 patients annually.
Ebola virus appears sporadically in endemic areas of the former Zaire and Sudan. Ebola virus also has been reported in Gabon, the Ivory Coast, and Uganda. Outbreaks appear to propagate in hospital settings, often involving health care providers.
Yellow fever continues to be a serious problem in tropical areas of South America and Africa, where vaccination is not widespread. The World Health Organization estimates that approximately 200,000 cases per year occur in Africa.
Dengue HF is endemic in Southeast Asia, Africa, Central America, and South America, and the WHO estimates that 50-100 million cases occur annually. In the first 3 months of 2011, Rio de Janeiro had already recorded more than 10,000 cases of dengue infection.[8]
Mortality/Morbidity
Case-fatality rates of patients with VHF vary from less than 10% (eg, in dengue HF) to approximately 90%, as has been reported in patients with Ebola-Zaire and the recent Angola Marburg outbreak. The most recent outbreak of Ebola-Sudan in Uganda had a 50% case-fatality rate.
Complications from VHF infection include retinitis, orchitis, hepatitis, transverse myelitis, and uveitis. In patients who recover from Lassa fever infection, deafness is the most common complication. Spontaneous abortion also is common. Renal insufficiency is associated with HFRS infection.
Race
No racial predilection has been identified, although cases have originated in African areas.
Sex
No predilection for either sex has been identified.
Age
VHF affects all ages according to exposure and local demographics.
Simpson SQ, Spikes L, Patel S, Faruqi I. Hantavirus pulmonary syndrome. Infect Dis Clin North Am. Mar 2010;24(1):159-73. [Medline].
Normile D. Emerging infectious diseases. Scientists puzzle over Ebola-Reston virus in pigs. Science. Jan 23 2009;323(5913):451. [Medline].
Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. Nov 2008;4(11):e1000212. [Medline].
Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, et al. Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. Mar 26 2009;[Medline].
Lupi O. Mosquito-borne hemorrhagic fevers. Dermatol Clin. Jan 2011;29(1):33-8. [Medline].
Rivers MN, Alexander JL, Rohde RE, Pierce JR Jr. Hantavirus pulmonary syndrome in Texas: 1993-2006. South Med J. Jan 2009;102(1):36-41. [Medline].
CDC. Locally acquired Dengue--Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep. May 21 2010;59(19):577-81. [Medline].
Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med. Jan 2011;12(1):90-100. [Medline].
Lee AM, Pasquato A, Kunz S. Novel approaches in anti-arenaviral drug development. Virology. Mar 15 2011;411(2):163-9. [Medline]. [Full Text].
Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, Patterson J, et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. Feb 1 2011;29(6):1248-57. [Medline].
Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. Feb 1 2010;201(3):370-7. [Medline].
Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. Jan 2007;3(1):e2. [Medline]. [Full Text].
Sarwar UN, Sitar S, Ledgerwood JE. Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine. Travel Med Infect Dis. Jun 26 2010;[Medline].
Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ. Mar 23 2009;338:b1223. [Medline].
Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A. Effective post-exposure treatment of Ebola infection. PLoS Pathog. Jan 2007;3(1):e2. [Medline].
Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. Dec 15 2010;51(12):1435-41. [Medline].
Borchert M, Muyembe-Tamfum JJ, Colebunders R, et al. Short communication: a cluster of Marburg virus disease involving an infant. Trop Med Int Health. Oct 2002;7(10):902-6. [Medline].
CDC. Imported Lassa fever--New Jersey, 2004. MMWR Morb Mortal Wkly Rep. Oct 1 2004;53(38):894-7. [Medline].
CDC. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb Mortal Wkly Rep. Feb 9 2001;50(5):73-7. [Medline].
CDC. Update: management of patients with suspected viral hemorrhagic fever--United States. MMWR Morb Mortal Wkly Rep. 1995;44(25):475-9. [Medline]. [Full Text].
Colebunders R, Borchert M. Ebola haemorrhagic fever--a review. J Infect. 2000;40(1):16-20. [Medline].
Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. Mar 5 2011;377(9768):849-62. [Medline].
Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. J Virol. Aug 2000;74(15):6777-83. [Medline]. [Full Text].
Fisher-Hoch SP, McCormick JB. Lassa fever vaccine. Expert Rev Vaccines. Apr 2004;3(2):189-97. [Medline].
Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. Dec 9 2008;26(52):6894-900. [Medline].
Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med. Sep 21 2004;6(20):1-24. [Medline].
Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines. Dec 2003;2(6):777-89. [Medline].
Hartman AL, Towner JS, Nichol ST. Ebola and marburg hemorrhagic fever. Clin Lab Med. Mar 2010;30(1):161-77. [Medline].
Holmes GP, McCormick JB, Trock SC, et al. Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med. 1990;323(16):1120-3. [Medline].
Jahrling PB. Viral hemorrhagic fevers. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. 1997.
Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P. Fruit bats as reservoirs of Ebola virus. Nature. Dec 1 2005;438(7068):575-6. [Medline].
Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. Aug 2004;4(8):487-98. [Medline].
McGovern TW, Christopher GW, Eitzen EM. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol. Mar 1999;135(3):311-22. [Medline].
Peters CJ, LeDuc JW. Ebola: the virus and the disease. J Infect Dis. 1999;179 (Suppl 1):ix-xvi. [Medline]. [Full Text].
Schmidt AC. Response to dengue fever--the good, the bad, and the ugly?. N Engl J Med. Jul 29 2010;363(5):484-7. [Medline].
Ströher U, Feldmann H. Progress towards the treatment of Ebola haemorrhagic fever. Expert Opin Investig Drugs. Dec 2006;15(12):1523-35. [Medline].
Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. Apr 2004;78(8):4330-41. [Medline].
| Virus Family | Disease (Virus) | Natural Distribution | Usual Source of Human Infection | Incubation (Days) |
| Arenaviridae | ||||
| Arenavirus | Lassa fever | Africa | Rodent | 5-16 |
| Argentine HF (Junin) | South America | Rodent | 7-14 | |
| Bolivian HF (Machupo) | South America | Rodent | 9-15 | |
| Brazilian HF (Sabia) | South America | Rodent | 7-14 | |
| Venezuelan HF (Guanarito) | South America | Rodent | 7-14 | |
| Bunyaviridae | ||||
| Phlebovirus | Rift Valley fever | Africa | Mosquito | 2-5 |
| Nairovirus | Crimean-Congo HF | Europe, Asia, Africa | Tick | 3-12 |
| Hantavirus | Hemorrhagic fever with renal syndrome, hantavirus pulmonary syndrome | Asia, Europe, worldwide | Rodent | 9-35 |
| Filoviridae | ||||
| Filovirus | Marburg and Ebola | Africa | Unknown | 3-16 |
| Flaviviridae | ||||
| Flavivirus | Yellow fever | Tropical Africa, South America | Mosquito | 3-6 |
| Dengue HF | Asia, Americas, Africa | Mosquito | Unknown for dengue HF, 3-5 for dengue |

